- Home
- LFVN vs XFOR Comparison
LFVN vs XFOR Comparison
Compare LFVN & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFVN
- XFOR
- Stock Information
- Founded
- LFVN N/A
- XFOR 2014
- Country
- LFVN United States
- XFOR United States
- Employees
- LFVN N/A
- XFOR N/A
- Industry
- LFVN Biotechnology: Pharmaceutical Preparations
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFVN Health Care
- XFOR Health Care
- Exchange
- LFVN Nasdaq
- XFOR Nasdaq
- Market Cap
- LFVN 145.2M
- XFOR 84.3M
- IPO Year
- LFVN N/A
- XFOR N/A
- Fundamental
- Price
- LFVN $10.74
- XFOR $2.90
- Analyst Decision
- LFVN Strong Buy
- XFOR Strong Buy
- Analyst Count
- LFVN 2
- XFOR 3
- Target Price
- LFVN $30.50
- XFOR $34.17
- AVG Volume (30 Days)
- LFVN 163.2K
- XFOR 1.6M
- Earning Date
- LFVN 10-28-2025
- XFOR 11-12-2025
- Dividend Yield
- LFVN 1.68%
- XFOR N/A
- EPS Growth
- LFVN 226.09
- XFOR N/A
- EPS
- LFVN 0.75
- XFOR N/A
- Revenue
- LFVN $228,530,000.00
- XFOR $32,774,000.00
- Revenue This Year
- LFVN $12.65
- XFOR $1,313.84
- Revenue Next Year
- LFVN $12.43
- XFOR N/A
- P/E Ratio
- LFVN $14.27
- XFOR N/A
- Revenue Growth
- LFVN 14.17
- XFOR 5721.31
- 52 Week Low
- LFVN $9.83
- XFOR $1.35
- 52 Week High
- LFVN $27.38
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- LFVN 35.05
- XFOR 50.10
- Support Level
- LFVN $10.39
- XFOR N/A
- Resistance Level
- LFVN $12.10
- XFOR $3.79
- Average True Range (ATR)
- LFVN 0.94
- XFOR 0.37
- MACD
- LFVN -0.24
- XFOR -0.24
- Stochastic Oscillator
- LFVN 12.19
- XFOR 60.66
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.